Aethon is the leading maker of practical, dependable courier robots for hospitals. Our team consists of hospital environment experts with over 100 years combined robotic experience in healthcare, so we understand the people and processes involved in running a hospital. We've used that knowledge to develop an automated technology platform that helps increase productivity and staff satisfaction, while saving hospitals time and money.
www.aethon.com
MyoScience Inc., founded in 2005 with headquarters in Redwood City, California, is a clinical development stage company dedicated to developing and commercializing innovative technology driven products for aesthetic medicine.
www.myoscience.com
Lab21 is a global provider of state-of-the-art diagnostic products and services, supporting healthcare and environmental markets. Established in 2005 with the vision of providing 21st century diagnostics the company’s main objective is to protect the health of people and the environment. We believe that ‘prevention is better than cure’ and we aim to provide information that helps to protect from the health problems of tomorrow.
www.lab21.com
EffRx, Inc. is a drug delivery company that utilizes value-added drug delivery technologies to improve the performance of established pharmaceuticals. The company applies its technologies to well established, proven compounds to develop reformulated products with reduced gastrointestinal side effects, better absorption, and faster onset of action. EffRx develops novel prescription and OTC pharmaceuticals at relatively low development cost and risk, shorter time to market and with premium pricing compared with generics.
www.effrx.com
Based in Waltham Massachusetts, EyeGate Pharma is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGate® II. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both preclinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic disease or diseases in the mid and posterior segments of the eye is less than adequate. We believe the EyeGate® II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease.
www.eyegatepharma.com